SGMT
Sagimet Biosciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SGMT
Sagimet Biosciences Inc.
A clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN)
Sagimet Biosciences Inc., 155 Bovet Road, Suite 303, San Mateo, California 94402
--
Sagimet Biosciences Inc., incorporated in Delaware on December 19, 2006 as 3-V Biosciences, Inc., is headquartered in San Mateo, California. The company changed its name from 3-V Biosciences, Inc. to Sagimet Biosciences Inc., in August 2019. The company is a clinical-stage biopharmaceutical company dedicated to the development of internally discovered combinations of selective fatty acid synthase inhibitors for the treatment of diseases caused by dysfunction of lipid metabolism.
Company Financials
EPS
SGMT has released its 2025 Q3 earnings. EPS was reported at -0.4, versus the expected -0.39, missing expectations. The chart below visualizes how SGMT has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
